When a Protein Design Company Goes Public, Bio AI Stops Being a Demo
One of the most revealing bio AI stories from the last couple of weeks is not a paper or a benchmark. It is a financing event. Generate Biomedicines raised about $400 million in a U.S. IPO, positioning itself as a company that uses AI to accelerate protein based therapeutics